Boston Therapeutics announced the addition of three accomplished and well credentialed scientists and clinicians to its newly created Scientific Advisory Board. The company is actively establishing clinical roadmaps for their patented investigative compounds in the US, Europe and Asia. John Amatruda an Adjunct Professor of Medicine, Endocrinology at Yale University, Former Senior Vice President & Franchise Head, Diabetes & Obesity, Merck & Co., Inc. Makaranda Jawadekar is Former Pfizer, Worldwide BioPharmaceutical Businesses, Portfolio Management and Analytics, as well as R & D, External Alliance Management, Contracting, Outsourcing, Benchmarking, Drug Delivery Systems assessment, Formulations, Clinical Supply Mfg and Packaging, CTM, Pharmaceutics, Pharm Sciences, Performance Metrics evaluations and assessment, Asia R & D. Dr. Jawadekar has broad experience in pharmaceutics and extensive networks in the US, EU, India and other parts of Asia including Japan and China. Richard Pittner, PhD is former Amylin, Senior Director and Head of Discovery Biology, Former Eli Lilly and Company Senior Director and Head Global External Research & Development (GERD), Bio-Medicines Business Unit, Former Pfizer Senior Director and Head External R&D Innovation Head for Cardiovascular Metabolic and Entero/Endocrine Disease.